Your browser doesn't support javascript.
loading
Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial.
Leypoldt, Lisa B; Besemer, Britta; Asemissen, Anne Marie; Hänel, Mathias; Blau, Igor Wolfgang; Görner, Martin; Ko, Yon-Dschun; Reinhardt, Hans Christian; Staib, Peter; Mann, Christoph; Lutz, Raphael; Munder, Markus; Graeven, Ullrich; Peceny, Rudolf; Salwender, Hans; Jauch, Anna; Zago, Manola; Benner, Axel; Tichy, Diana; Bokemeyer, Carsten; Goldschmidt, Hartmut; Weisel, Katja C.
Afiliação
  • Leypoldt LB; Department of Hematology, Oncology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Besemer B; Department of Hematology, Oncology, Immunology, Rheumatology and Pulmonology, University Hospital of Tuebingen, Tuebingen, Germany.
  • Asemissen AM; Department of Hematology, Oncology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Hänel M; Department of Hematology, Oncology and Bone Marrow Transplantation, Klinikum Chemnitz, Chemnitz, Germany.
  • Blau IW; Department of Internal Medicine, Charité University Medicine Berlin, Berlin, Germany.
  • Görner M; Department of Hematology, Oncology and Palliative Care, Klinikum Bielefeld Mitte, Bielefeld, Germany.
  • Ko YD; Department of Internal Medicine, Hematology and Oncology, Johanniter Krankenhaus Bonn, Bonn, Germany.
  • Reinhardt HC; Department of Hematology and Stem Cell Transplantation, University Hospital Essen, University Duisburg-Essen, German Cancer Consortium (DKTK partner site Essen), Essen, Germany.
  • Staib P; Department of Hematology and Oncology, St. Antonius Hospital Eschweiler, Eschweiler, Germany.
  • Mann C; Department of Hematology, Oncology and Immunology, University Hospital of Gießen and Marburg, Marburg, Germany.
  • Lutz R; University Hospital Heidelberg, Internal Medicine V and National Center for Tumor Diseases (NCT), Heidelberg, Germany.
  • Munder M; Department of Internal Medicine III, University Medical Center Mainz, Mainz, Germany.
  • Graeven U; Department of Hematology, Oncology and Gastroenterology, Maria Hilf Kliniken, Mönchengladbach, Germany.
  • Peceny R; Department of Oncology, Hematology and Stem Cell Transplantation, Klinikum Osnabrück, Osnabrück, Germany.
  • Salwender H; Asklepios Tumorzentrum Hamburg, AK Altona and AK St. Georg, Hamburg, Germany.
  • Jauch A; Institute of Human Genetics, University of Heidelberg, Heidelberg, Germany.
  • Zago M; Center for Clinical Trials, University Hospital of Tuebingen, Tuebingen, Germany.
  • Benner A; Division of Biostatistics, German Cancer Research Center (DKFZ) Heidelberg, Heidelberg, Germany.
  • Tichy D; Division of Biostatistics, German Cancer Research Center (DKFZ) Heidelberg, Heidelberg, Germany.
  • Bokemeyer C; Department of Hematology, Oncology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Goldschmidt H; University Hospital Heidelberg, Internal Medicine V and National Center for Tumor Diseases (NCT), Heidelberg, Germany.
  • Weisel KC; Department of Hematology, Oncology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. k.weisel@uke.de.
Leukemia ; 36(3): 885-888, 2022 03.
Article em En | MEDLINE | ID: mdl-34732857
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Oligopeptídeos / Dexametasona / Protocolos de Quimioterapia Combinada Antineoplásica / Anticorpos Monoclonais Humanizados / Lenalidomida / Mieloma Múltiplo Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Oligopeptídeos / Dexametasona / Protocolos de Quimioterapia Combinada Antineoplásica / Anticorpos Monoclonais Humanizados / Lenalidomida / Mieloma Múltiplo Idioma: En Ano de publicação: 2022 Tipo de documento: Article